文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

孟买耐药结核病患者同时使用贝达喹啉和德拉马尼的疗程结束结局

One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该回顾性队列研究基于印度孟买无国界医生诊所2016年2月至2018年2月纳入的70例耐药结核病患者,这些患者同时接受贝达喹啉和德拉马尼治疗至少4周。

要点

  • 同时使用贝达喹啉和德拉马尼超过24周的方案在耐药结核病中有效且可安全门诊给药。
  • 70例患者中49例(70%)获得成功的疗程结束结局。
  • 30例(43%)患者报告严重不良事件,包括5例QTc延长。

核心结论

  • 含贝达喹啉和德拉马尼超过24周的方案对耐药结核病有效,可在门诊安全给药。

研究设计与样本

  • 回顾性队列研究,基于常规收集的项目数据,纳入2016年2月至2018年2月期间在孟买无国界医生诊所启动含贝达喹啉和德拉马尼(同时使用至少4周)治疗的耐药结核病患者70例。

主要发现

  • 70例患者中位年龄25岁(IQR 22-32),56%为女性,除1例外均为氟喹诺酮类耐药。
  • 贝达喹啉和德拉马尼的中位暴露时间为77周(IQR 43-96)。
  • 69%的患者在治疗24周前培养转阴,61例(87%)将贝达喹啉和德拉马尼使用延长至24周以上。
  • 49例(70%)患者报告成功的疗程结束结局。

临床怎么用

  • 对于治疗选择有限的耐药结核病患者,可考虑同时使用贝达喹啉和德拉马尼超过24周,并在门诊环境下监测严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Médecins Sans Frontières Clinic in Mumbai, India, has been providing concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with drug-resistant tuberculosis (DR-TB) and limited therapeutic options, referred from other healthcare institutions, since 2016. The study documents the end-of-treatment outcomes, culture-conversion rates, and serious adverse events (SAEs) during treatment. METHODS: This was a retrospective cohort study based on routinely collected program data. In clinic, treatment regimens are designed based on culture drug sensitivity test patterns and previous drug exposures, and are provided for 20-22 months. BDQ and DLM are extended beyond 24 weeks as off-label use. Patients who initiated DR-TB treatment including BDQ and DLM (concomitantly for at least 4 weeks) during February 2016-February 2018 were included. RESULTS: Of the 70 patients included, the median age was 25 (interquartile range [IQR], 22-32) years and 56% were females. All except 1 were fluoroquinolone resistant. The median duration of exposure to BDQ and DLM was 77 (IQR, 43-96) weeks. Thirty-nine episodes of SAEs were reported among 30 (43%) patients, including 5 instances of QTc prolongation, assessed as possibly related to BDQ and/or DLM. The majority (69%) had culture conversion before 24 weeks of treatment. In 61 (87%), use of BDQ and DLM was extended beyond 24 weeks. Successful end-of-treatment outcomes were reported in 49 (70%) patients. CONCLUSIONS: The successful treatment outcomes of this cohort show that regimens including concomitant BDQ and DLM for longer than 24 weeks are effective and can be safely administered on an ambulatory basis. National TB programs globally should scale up access to life-saving DR-TB regimens with new drugs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Das M, Dalal A, Laxmeshwar C, et al. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India. Clin Infect Dis. 2021. PMID: 33079176. doi:10.1093/cid/ciaa1577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。